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INTRODUCTION
Alopecia areata (AA) is a disfiguring disease characterized
by nonscarring hair loss. It is a chronic inflammatory disor-
der affecting both the hair follicles and the nail apparatus,
with T-lymphocyte infiltration and chemokine expression
being characteristic in involved tissue (1). The prevalence
rates of AA is 0.1% in the world population (2) and 0.9-6.9%
in Korea (3). The association of AA with autoimmune dis-
eases including thyroid disorders, pernicious anemia and
vitiligo is well established and alopecia areata itself is con-
ventionally regarded as an autoimmune disease (4). The impor-
tance of immune-mediated mechanism, but non necessarily
autoimmunity, in the pathogenesis of alopecia areata is sug-
gested by the therapeutic efficacy of immunosuppressive
drugs such as cyclosporin A, tacrolimus and corticosteroids. 
It is well known that locally infiltrating lymphocytes have
been implicated as effector cells being responsible for the
reversible alteration of the hair follicles and the resulting hair
loss (5, 6). In general, the directional recruitment of leuko-
cytes is regulated by chemokines and their counteracting
chemokine receptors (7). Recently, in human models of AA it
was shown that the increased expression of chemokines includ-
ing monocyte chemoattractant protein-1 (MCP-1), monokine
induced by interferon- (MIG) might play a pivotal role in
the attraction of monocytes around the hair bulb (1). 
MCP-1 is a  -chemokine that is thought to be responsi-
ble for monocyte and lymphocytes T recruitment in acute
inflammatory conditions and may be an important media-
tor in chronic inflammation. In fact, it has been proposed
that MCP-1 may be responsible for tissue inflammation in
autoimmune diseases because its tissue expression in human
and experimental autoimmune models (8-11). Thus, genetic
polymorphism in the regulatory regions of the MCP-1 gene
could be implicated in the susceptibility or progression of
autoimmune disease. A biallelic A/G polymorphism at posi-
tion-2518 of the MCP-1 gene has been described. The poly-
morphism proved functionally important, as peripheral blood
mononuclear cells of individuals with G/G and A/G geno-
type produced significantly more MCP-1 after stimulation
with IL-1 than those with Caucasian wild-type A/A (12,
13). An association of the presence of G at position -2518
with the presence of cutaneous vasculitis could be shown in
patients with systemic lupus erythematosus (14) as well as
an association with development of coronary artery aneurysms
after acute Kawasaki disease (13). Furthermore, the G/G geno-
type was identified as a genetic risk factor for severe coronary
artery disease (15) and a correlation between the incidence
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Analysis of the Monocyte Chemoattractant Protein 1 -2518 Promoter
Polymorphism in Korean Patients with Alopecia Areata
Monocyte chemoattractant protein-1 (MCP-1) levels are increased in scalp lesions
of patients with alopecia areata (AA), suggesting a role in the development of AA.
Recently, a biallelic A/G polymorphism in the MCP-1 promoter at position -2518
has been found, influencing the level of MCP-1 expression in response to an inflam-
matory stimulus. We investigated whether the presence of these polymorphisms
were associated with AA in Korean population. 145 Korean patients with AA, 246
healthy subjects without clinical evidence of AA were screened for genotype with a
PCR-based assay. In the AA patients the frequency of the A and G alleles was 40.3
and 59.7%, respectively and the distribution of the A/A, A/G and G/G genotypes
was 19.3, 42.1 and 38.6%, respectively. Amongst the controls the frequency of the
A and G alleles was 39.8 and 60.2%, and the distribution of the A/A, A/G, G/G geno-
types in the same group was 17.5, 44.7 and 37.8%, respectively. There was no
significant difference in the allele frequencies and genotype distributions between
the patients and the controls (p=0.889, p=0.848, respectively). Our data indicates
that no association exists between the -2518A/G polymorphism of the MCP-1 gene
and susceptibility to alopecia areata.
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and severity of asthma and the G allele at position -2518
has been shown. These findings suggest an important role
for the MCP-1 and the A/G polymorphism in its regulatory
region in inflammatory processes. 
The MCP-1 gene polymorphism in AA patients has not
been reported yet. In this study, we performed a case-con-
trol study in 145 alopecia areata patients and 246 matched
Korean controls to analyze the possible influence of the poly-
morphism (A/G) at position -2518 of the MCP-1 gene in
the susceptibility of AA. 
MATERIALS AND METHODS
Patients and controls 
A total of 145 Korean patients with AA (70 men and 75
women) were examined at the Dermatology Clinic at the
Kyung Hee University Medical Center. A total of 246 healthy
subjects (80 men and 166 women), who had no clinical evi-
dence of AA, were recruited as controls (Table 1). This study
was approved by the ethics review committee of the Medical
Research Institute, Kyung Hee University Medical Center.
The clinical diagnosis of AA was based on the presence of
initially patchy alopecia with exclamation mark hairs and
the exclusion of other causes of alopecia. Detailed clinical
information was obtained from each patient, including age
at onset of first episode, family history, type of disease (patchy
alopecia, alopecia totalis [AT] and alopecia universalis [AU]),
duration of disease, presence of other autoimmune disease,
nail involvement, and other body sites hair loss. Clinical infor-
mation was updated at follow-up examinations. We divided
the AA patients into two subgroups according to disease
severity. Subgroup 1 contained patients with patchy disease
(patchy AA) and subgroup 2 patients with more extensive
hair loss (AT and AU) (16). Patchy AA can involve the scalp
or other body sites such as the beard area. In patchy AA (sub-
group 1) there are well demarcated, mainly circular areas of
hair loss typically 2-6 cm in diameter. In subgroup 2, hair
loss progresses until all the hair on the scalp has been lost
(AT); or to complete loss of the entire body hair (AU). We
also divided the AA patients into two subgroups on the basis
of age at onset of disease (17). The division of these subgroups
with a boundary at age 30 yr was in keeping with the distri-
bution of age at onset in our patients, which was bimodal
with peaks at approximately age 20-30 and 30-40 yr.
MCP-1 genotyping
Genomic DNA was prepared from heparinized venous
blood samples using a NucleoSpin DNA isolation kit (MA-
CHE-REY-NAGEL GmbH & Co., Duren, Germany). The
identification of the polymorphism was carried out using
PCR, followed by a restriction fragment length polymor-
phism (RFLP) assay, using a PvuII site, which is introduced
by the presence of the G nucleotide. The regulatory region
of the MCP-1 gene (from -2746 at -1817) was amplified
by polymerase chain-reaction (PCR) using the forward primer
5′ CCGAGATGTTCCCAGCACAG3′ and the reverse primer
5′ CTGCTTTGCTTGTGCCTCTT3′ . PCR was performed
using buffer 10× (10 mM Tris-HCl pH 9, 2.0 mM MgCl2,
50 mM KCl), 200  m dNTPs, 2.5 pmoles of each primer, 0.5
L of DNA, 0.5 U Taq polymerase (Pharmacia) and ddH2O
up to a final volume of 10  L. The following thermal profiles
were run: 94℃for 1 min, 55℃for 1 min, and 72℃for 1.5
min. After a final extension of 10 min at 72℃, 7  L of the
PCR products were resolved in 2% agarose gels stained with
ethidium bromide previous dilution in blue juice buffer to
check the expected 930-bp band. After checking, 8  L of
the PCR products were digested with 10 U of PvuII in 10×
buffer and H2O up to a final volume of 20  L at 37℃ for 2
hr 30 min. 
The resulting products were separated by gel-electrophore-
sis in 1.5% agarose gels, containing ethidium bromide in a
final concentration of 0.5  g/mL. Samples showing only a
930 bp band were assigned as A/A, samples showing two
bands of 708 and 222 bp were considered G/G and samples
showing three bands at 930, 708 and 222 bp were typed A/G. 
Statistical analysis
The distribution of the MCP-1 A/G genotypes for patients
and control subjects were compared by the chi-square ( 2)
test. p value less than 0.05 were considered as statistically
significant.
RESULTS
In the case-control study, genotype distributions and allele
frequencies of the MCP genetic marker in both AA and the
control population was analyzed (Table 2). In the AA patients
the frequency of the A and G alleles was 40.3 and 59.7%,
Alopecia areata
(n=145)
Healthy controls
(n=246)
Average age (yr, mean±SD) 28.90±13.22 51.0±12.60
No. of male/female 70/75 80/166
Onset age (yr, mean±SD) 27.43±13.82
Subgroups according to  (128/17)
disease severity (patchy 
AA/AT or AU)
Subgroups according to  (105/40)
age at onset (Onset age ≤30/
Onset age >30 yr)
Table 1. Clinical characteristics of the 145 Korean alopecia areata
patients and healthy controls
AA, alopecia areata; AT, alopecia totalis; AU, alopecia universalis.92 S.-B. Hong, S.-Y. Jin, H.-J. Park, et al.
respectively and the distribution of the A/A, A/G and G/G
genotypes was 19.3, 42.1 and 38.6%, respectively. Amongst
the controls the frequency of the A and G alleles was 39.8
and 60.2%, and the distribution of the A/A, A/G, G/G geno-
types in the same group was 17.5, 44.7 and 37.8%, respec-
tively. The observed genotype frequencies of the AA patient
(p=0.129) and the control population (p=0.574) did not show
significant difference predicted by the Hardy-Weinberg equa-
tion. When the observed control and patient genotype fre-
quencies were compared with expected values using 3×2
contingency table in a standard chi-square test (Table 2), there
was no significant difference (p=0.848). Also, there was no
significant difference in the allele frequencies between the
patients and the controls (p=0.889).
We then divided the patients into two subgroups (sub-
group 1 [patchy AA] and subgroup 2 [alopecia totalis and
alopecia universalis]) according to disease severity and also
into two further subgroups on age at onset of disease (sub-
group a [onset age ≤30] and subgroup b [onset age >30]).
Comparison of the genotype distributions and the allele fre-
quencies between each subgroup and the control population
revealed no significant difference (Table 3A, B). 
DISCUSSION
Although MCP-1 has been proposed as the main chemokine
responsible for initiating autoimmune tissue damage (8, 11,
18, 19), the association of polymorphisms in the regulatory
regions of the MCP-1 gene with alopecia areata has not been
studied until now. Recently, in human models of AA it was
shown that the increased expression of MCP-1 might play a
pivotal role in the attraction of monocytes around the hair
bulb (1). In addition, the MCP-1-2518G allele was found
to increase the MCP-1 expression (12). Therefore, we initially
hypothesized that the development of AA might have been
related to G allele in the MCP-1 gene polymorphism in AA
patients. The results of this study, however, did not support
this assumption. In this case-control study, the genotype
distribution and allelic frequencies showed no significant
Observed allele frequency (%)
No. A G
Observed genotype counts (%)
A/A A/G G/G
Expected genotype count*
A/A A/G G/G
p-
value
Control 492 196 (39.8%) 296 (60.2%) 43 (17.5%) 110 (44.7%) 93 (37.8%) 39 117 89 0.574*
Patients 290 117 (40.3%) 173 (59.7%) 28 (19.3%) 61 (42.1%) 56 (38.6%) 23 69 51 0.129*
p-value 0.889
� 0.848
�
Odds ratio  0.979 (0.728-1.316)
(95%CI)
Table 2. Distribution of alleles and genotypes for the A/G SNP in MCP-1 in alopecia areata and control population
*Observed vs. expected according to the Hardy-Weinberg equation, 
�
Controls vs. patients using the chi-square test with 2×2 contingency table, 
�
Con-
trols vs. patients using the chi-square test with 3×2 contingency table.
Observed genotype counts (%)
A/A A/G G/G
p-value
Control 43 (17.5%) 110 (44.7%) 93 (37.8%)
Patchy AA (subgroup 1) 1 (5.8%) 8 (47.1%) 8 (47.1%) 0.438*
AT/AU (subgroup 2) 27 (21.1%) 53 (41.4%) 48 (37.5%) 0.670*
Onset age ≤30 yr (subgroup a) 24 (22.9%) 41 (39.0%) 40 (38.1%) 0.435*
Onset age >30 yr (subgroup b) 4 (10.0%) 20 (50.0%) 16 (40.0%) 0.490*
Table 3A. Comparison of genotype distributions between each subgroup and the control population
*Controls vs. patients using the chi-square test with 3×2 contingency table.
Observed allele frequencies (%)
No. A G Odds ratio (95% CI)
p-value
Control 492 196 (39.8%) 296 (60.2%)
Patchy AA (subgroup 1) 256 107 (41.8%) 149 (58.2%) 0.922 (0.678-1.253) 0.604*
AT/AU (subgroup 2) 34 10 (29.4%) 24 (70.6%) 1.589 (0.744-3.396) 0.228*
Onset age ≤30 yr (subgroup a) 210 89 (42.4%) 121 (57.6%) 0.900 (0.649-1.250) 0.530*
Onset age >30 yr (subgroup b) 80 28 (35.0%) 52 (65.0%) 1.230 (0.751-2.015) 0.411*
Table 3B. Comparison of allele frequencies between each subgroup and the control population
*Controls vs. patients using the chi-square test with 2×2 contingency table.Genetic Polymorphism of MCP-1 and Alopecia Areata  93
difference between the patients population and the controls
(p=0.848, p=0.889, respectively).
There are several potential reasons why there was no asso-
ciation between the -2518A/G polymorphism and alopecia
areata. It is noteworthy that there are considerable differences
in the frequencies of these polymorphisms among the differ-
ent races. Indeed, it is well known that ethnicity and popu-
lation structure may strongly influence the role of genetic
risk factors in chronic inflammatory diseases including vari-
ous autoimmune diseases. The distribution of several gene
variations may be greatly different between various countries,
as well as among different area in the same countries. The
dominance of the G-type allele in Koreans, which were ob-
served in this present study, is contrasting to what has been
reported from Caucasians and AfroAmericans, where the
proportion of G allele was 29 and 22%, respectively (12).
Such reversed ratio was also observed in Japanese (13), sug-
gesting that the genotypic profile of MCP-1-2518 polymor-
phism varies greatly among ethnic groups. And, the -2518A/
G polymorphism may not be associated with alopecia areata.
Previously, it was shown that allelic frequency of -2518 poly-
morphism among patients with other autoimmune diseases
with increased serum MCP-1 level, such as rheumatoid arthri-
tis, systemic lupus erythematosus and adult-onset Still’s dis-
ease, is also similar to that of normal controls (20). In addi-
tion, in study about the chemokine expression pattern of AA,
Benoit et al. have demonstrated that MCP-1 expression does
not appear to be a particular feature of AA due to showing
MCP-1 expression by keratinocytes of the inner root sheath
but only weak expression around the hair follicles. And che-
mokine expression patterns did not appear to correlate with
clinical severity such as extent of hair loss, number of AA
episodes, or presence of associated diseases (1). These findings
argue against a role of MCP-1 -2518A/G polymorphism
for susceptibility to alopecia areata.
In conclusion, this study found no association of -2518A/G
polymorphism in the distal regulatory region of the MCP-1
with alopecia areata susceptibility or severity in a Korean
population. However, it is noteworthy that there are consid-
erable differences in the frequencies of these polymorphisms
among the different races. This variation may contribute to
the pathogenesis of alopecia areata and must be considered
in gene-association studies in different ethnic populations. 
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